Plakous Therapeutics

Plakous Therapeutics is a private, pre-clinical stage biotech developing a novel biologic derived from the human placenta. Its lead asset, Human Placental Extract (HPE), is being investigated for its anti-inflammatory and pro-regenerative properties, with an initial focus on severe pediatric gastrointestinal conditions like necrotizing enterocolitis (NEC). The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) and significant non-dilutive funding from the NIH, positioning it to advance its first candidate into clinical trials. Its long-term vision is to become a leader in birth tissue-derived therapeutics for a range of inflammatory diseases.

Proprietary Human Placental Extract (HPE), a complex biologic containing cytokines and growth factors with dual anti-inflammatory and pro-proliferative capabilities designed to orchestrate tissue repair.

In NEC, direct competition is limited, though other preventive strategies (e.g., probiotics, breast milk fortifiers) exist. More broadly, Plakous competes in the large and crowded fields of regenerative medicine and cytokine/growth factor therapies, where many companies are developing targeted, recombinant protein drugs versus Plakous's complex natural extract.